Torsemide and Bumetanide Have Superior Oral Absorption
Torsemide and bumetanide are the loop diuretics with the best oral absorption, with bioavailability of approximately 80-100% and 80-95% respectively, compared to furosemide's highly variable and often poor bioavailability of 12-112%. 1
Pharmacokinetic Differences Between Loop Diuretics
The most recent and authoritative guideline evidence (2025) explicitly states that "torsemide and bumetanide exhibit greater oral bioavailability" compared to furosemide 1. This pharmacochemical difference has important clinical implications:
Furosemide's Absorption Problems
- Extremely erratic absorption with bioavailability ranging from 12% to 112% 2
- Unpredictable absorption, particularly problematic in patients with intestinal edema from heart failure 1
- Despite being the most commonly prescribed loop diuretic, its variable absorption makes it less reliable for oral administration 3, 4
Torsemide's Advantages
- Almost complete bioavailability (approaching 100%) 5
- Longer elimination half-life and duration of action (12-16 hours) 3, 4
- More predictable and consistent absorption
- Additional potential benefits including favorable RAAS modulation 1
Bumetanide's Profile
- High oral bioavailability (80-95%)
- Approximately 40 times more potent than furosemide on a milligram-per-milligram basis 6
- Shorter duration of action (4-6 hours) compared to torsemide 3, 4
Clinical Implications
The 2013 ACC/AHA guideline explicitly acknowledges this issue, stating that "some patients respond more favorably to other agents in this category (eg, bumetanide, torsemide) because of their increased oral bioavailability" 3. The 2022 ACC/AHA/HFSA guideline reiterates this point nearly verbatim, noting that patients may respond better to bumetanide or torsemide "potentially because of their increased oral bioavailability" 4.
When Superior Absorption Matters Most
- Outpatient management where consistent oral absorption is critical
- Patients with intestinal edema from heart failure, where furosemide absorption becomes even more unpredictable 1
- Transition from IV to oral therapy at hospital discharge, where reliable absorption prevents readmission
- Patients requiring once-daily dosing for adherence (torsemide's longer duration of action is advantageous here)
Important Caveats
While torsemide and bumetanide have superior bioavailability, the choice of loop diuretic should also consider:
- Cost considerations: Furosemide remains less expensive, which may be relevant for some patients
- Availability: Torsemide is not available as an IV formulation in the United States 7
- Dosing frequency: Torsemide's longer duration allows once-daily dosing, potentially improving adherence
- Clinical experience: Most outcome data in heart failure trials were generated using furosemide as background therapy
The bottom line: If oral absorption reliability is the primary concern, torsemide is the optimal choice given its near-complete bioavailability and once-daily dosing, with bumetanide as an excellent alternative when shorter duration of action is preferred.